Tasos Konidaris
CIK: 0001320982
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Amneal Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (28 total)
- Mar 4, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct22K shares at avg. $13.30$293K - Mar 4, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct44K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct24.3K shares at avg. $13.31$323K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct14.3K shares at avg. $13.31$190K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct458.7K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct229.8K shares at avg. $13.31$3.1M - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct45.3K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct16.2K shares at avg. $13.31$215K - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct57.3K shares- - Mar 3, 2026AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct28.5K shares- - Mar 2, 2026AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectPerformance-Based Restricted Stock Units
72.6K shares- - Mar 2, 2026AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
72.6K shares- - Aug 15, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct219.2K shares at avg. $9.43$2.1M - Aug 14, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct119.2K shares at avg. $9.30$1.1M - Aug 13, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct161.4K shares at avg. $9.22$1.5M - Mar 5, 2025AMRX
Amneal Pharmaceuticals, Inc.
Sale(S)Direct100K shares at avg. $8.91$891K - Mar 4, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct22.5K shares at avg. $8.84$199K - Mar 4, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct44K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
114.2K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct45.3K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct16.4K shares at avg. $8.76$143K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct57.3K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct24.4K shares at avg. $8.76$214K - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Exercise(M)Direct181.2K shares- - Mar 3, 2025AMRX
Amneal Pharmaceuticals, Inc.
Tax Payment(F)Direct92.7K shares at avg. $8.76$812K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 22,035 | $13.30 | $293,066 | Direct |
| Mar 4, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 43,982 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 24,251 | $13.31 | $322,781 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 14,298 | $13.31 | $190,306 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 458,716 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 229,817 | $13.31 | $3,058,864 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 45,290 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 16,182 | $13.31 | $215,382 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 57,339 | - | $0 | Direct |
| Mar 3, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 28,538 | - | $0 | Direct |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Performance-Based Restricted Stock Units | 72,622 | - | - | Direct |
| Mar 2, 2026 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 72,622 | - | - | Direct |
| Aug 15, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 219,159 | $9.43 | $2,066,669 | Direct |
| Aug 14, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 119,206 | $9.30 | $1,108,616 | Direct |
| Aug 13, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 161,365 | $9.22 | $1,487,785 | Direct |
| Mar 5, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Sale(S) | 100,000 | $8.91 | $891,000 | Direct |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 22,497 | $8.84 | $198,873 | Direct |
| Mar 4, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 43,981 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 114,155 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 45,290 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 16,373 | $8.76 | $143,427 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 57,340 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 24,374 | $8.76 | $213,516 | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Exercise(M) | 181,159 | - | - | Direct |
| Mar 3, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Tax Payment(F) | 92,663 | $8.76 | $811,728 | Direct |
1-25 of 28 transactions
About Konidaris Tasos
Konidaris Tasos (SEC CIK 0001320982) files insider reports with the SEC as Executive Vice President & CFO of Amneal Pharmaceuticals, Inc. (AMRX).
Signal8 holds 6 ownership filings by Konidaris Tasos, all Form 4s, filed between Mar 4, 2025 and Mar 5, 2026. Those filings report 28 transactions, from Mar 1, 2025 to Mar 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Konidaris Tasos's filings is in BRIDGEWATER, NJ.
Recent filings by Konidaris Tasos
- Mar 4, 2026: Tax withholding of AMRX shares (Form 4, code F).
- Mar 4, 2026: Option exercise of AMRX shares (Form 4, code M).
- Mar 3, 2026: Tax withholdings of AMRX shares (2 lines, Form 4, code F).
- Mar 3, 2026: Option exercise of AMRX shares (Form 4, code M).
- Mar 3, 2026: Tax withholding of AMRX shares (Form 4, code F).
Other insiders filing for Amneal Pharmaceuticals, Inc. (AMRX)
- BUCHI J KEVIN, Director
- BOYER ANDREW S, Executive Vice President
- Kiely John, Director
- Shah Nikita, Executive Vice President
- Daly Jason B., EVP, Chief Legal Officer
- Patel Tushar Bhikhubhai, 10% Owner